- |||||||||| KF-0210 / Keythera Pharma
Discovery of EP4 receptor antagonist KF-0210 for the treatment of cancers (Section 45; Poster Board #11) - Mar 14, 2023 - Abstract #AACR2023AACR_3609;
It shows the inhibitory effect on tumor growth in mouse models of colorectal and breast cancers. The combination treatment of KF-0210 and PD-1/PD-L1 antibodies shows a superior therapeutic effect compared to the monotherapy of each treatment.
- |||||||||| KF-0210 / Keythera Pharma
Enrollment open, Metastases: A Study of KF-0210 in Advanced Solid Tumors Patients (clinicaltrials.gov) - Jan 26, 2021
P1, N=64, Recruiting,
The combination treatment of KF-0210 and PD-1/PD-L1 antibodies shows a superior therapeutic effect compared to the monotherapy of each treatment. Not yet recruiting --> Recruiting
|
